Sanofi
SNY Nasdaq· Pharmaceutical Preparations
Last close · Oct 30, 2026
$44.34
KIRA · Stoqly’s AI analyst, in plain words
- Sanofi made $8.8B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 6.7% a year.
- Sanofi returned $11.1B to shareholders in fiscal 2025. The diluted share count fell 2.4%.
- Sanofi owes $13.0B more than it holds in cash.
Market cap
$108.7B
P/E
12.3x
Revenue
—
Net income
$8.8B
Free cash flow
—
Operating margin
—
Sanofi in 30 seconds · fiscal 2025
Does it make a profit?
$8.8B
Yes. It made $8.8B of profit last year.
Is debt under control?
$13.0B
Risky. It owes more than it holds in cash and has no operating profit to repay it.
How healthy are the accounts?
5 / 7
Mixed. It passes 5 of 7 health tests.
How is the share priced?
12.3x
One share costs 12.3 times its yearly profit per share.
What Sanofi does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Feb 17, 2026
- Legal name
- Sanofi
- CIK
- 0001121404
Sanofi · SNY · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | $7.4B | $8.8B | $5.8B | $6.0B | $8.8B |
| Diluted EPS | $2.93 | $3.50 | $2.33 | $2.40 | $3.59 |
| Cash | |||||
| Cash from operations | $12.4B | $11.1B | $11.1B | $9.8B | $12.1B |
| Dividends paid | $4.7B | $4.4B | $4.8B | $5.1B | $5.4B |
| Share buybacks | $452M | $522M | $641M | $327M | $5.7B |
| Share count change | −0.3% | 0.0% | −0.0% | −0.0% | −2.4% |
| Debt and strength | |||||
| Cash and short-term investments | $11.4B | $13.6B | $9.6B | $7.7B | $9.0B |
| Debt incl. finance leases | $22.9B | $20.5B | $18.3B | $16.8B | $22.0B |
| Shareholders' equity | $77.8B | $79.8B | $81.8B | $80.5B | $83.9B |
| Current ratio | — | 1.4x | 1.3x | 1.5x | 1.1x |
| Interest coverage | 22.1x | 23.6x | 5.4x | 6.8x | 11.3x |
| Returns and quality | |||||
| Return on capital | 8.5% | 9.7% | 6.6% | 6.9% | 5.8% |
| Return on equity | 9.5% | 11.2% | 7.2% | 7.4% | 10.7% |
| Return on tangible equity | — | 253.7% | 1,667.1% | 50.4% | 196.5% |
| Piotroski F-score | — | — | 5 | 7 | 5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Sanofi · SNY · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $44.34 a share, the company is worth $108.7B: 12.3 times its earnings of the last four quarters.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001121404). Latest version: stoqly.net/companies/sny. Data updated November 1, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.